Orion Corporation

Jouko Levijoki

Heimo O Haikala

Piero Pollesello

Juha Kaivola

Jarmo J Pystynen

Carola Tilgmann

Petri Kaheinen

Arto J Karjalainen

Pentti T Nore

Kari L&ouml;nnberg

Lasse Saloranta

Aino K Pippuri

Anne M Luiro

Eija Tiainen

Sirpa Rasku

Martti Ovaska

Seppo Parhi

Jukka Tenhunen

Reijo B&auml;ckstr&ouml;m

Leena Otsomaa

Tuula Koskelainen

Johanna Kokkonen

Ismo Ulmanen

Sari Pappinen

The invention relates to a method for treating or preventing nausea and vomiting. The method comprises administering an eye drop composition comprising palonosetron or a pharmaceutically acceptable salt thereof to the eye of the subject. The ocular administration results in fast systemic absorption, improved bioavailability compared to oral route and extended elimination time.

Palonosetron for the treatment or prevention of nausea and vomiting

The invention relates to a method of inducing emesis in animals, particularly companion animals such as dogs and cats, in situations where vomiting is desired. The method comprises administering an eye drop composition comprising a selective Dfamily dopamine agonist as an active ingredient to the eye of the animal to induce emesis. The method and the composition are useful in situations involving ingestion of a potentially toxic substance or foreign body by the animal.

Veterinary method for inducing emesis

A method for the prevention of thrombotic, embolic and/or hemorrhagic disorders, such as cerebral infarction (stroke) or myocardial infarction, by administering levosimendan or its metabolite (II) or any of their pharmaceutically acceptable salts to a mammal in need of such prevention.

Method for the prevention of thromboembolic disorders

Therapeutically active compounds of formula (I) or (II): wherein the variables in formulas (I) and (II) are defined in the description, and pharmaceutically acceptable salts and esters thereof. The compounds are potent inhibitors of Na/Caexchange mechanism.

Pyridine derivatives useful for inhibiting sodium/calcium exchange system

A combination therapy for the treatment of heart failure, particularly acute heart failure, comprises administering a combination of levosimendan or a pharmaceutically acceptable salt thereof and a calcium ion source and/or an intracellular calcium increasing agent to a patient. The combination shows a synergistic effect even at doses having no effect if administered alone.

Method for the treatment of heart failure

Pyridazinyl phenyl hydrazones useful against congestive heart failure

A method for obtaining direct dilatation of the coronary arteries by administering a therapeutically effective amount of a phospholamban inhibitor is described. Compounds which are effective in relieving the inhibitory effects of phospholamban on cardiac sarcoplasmic reticulum Ca,-ATPase are also described.

Phospholamban inhibitors and a method for increasing coronary flow

A method for the prevention and treatment of stunning of the heart subsequent to ischemia-reperfusion is described. The method comprises administering a therapeutically effective amount of a phospholamban inhibitor to a patient. Phospholamban inhibitors relieve the inhibitory effect of phospholamban on cardiac sarcoplasmic reticulum Ca.sup.2+ -ATPase.

Method for the prevention and treatment of stunned myocardium

A method for the treatment of neurohumoral imbalance caused by alterations of cardiac function to prevent the development of heart failure comprises administering an effective amount of (R)-�4-(1,4,5,6-tetrahydro-6-oxo-3-pyridazinyl)phenyl!acetamide to a mammal in need of such treatment.

Use of a pyridazinone derivative

Growing community of inventors

Helsinki, Finland

Jouko Levijoki